Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | DTYMK | P23919 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988825 | 0.90 | CSF1R (0.44) | CSF1RKITPDGFRAACHEL3MBTL1 | |
| SCHEMBL22978560 | 0.80 | GPR84 (0.41) | CSF1RKITPDGFRA | |
| SCHEMBL22978450 | 0.74 | ELANE (0.39) | L3MBTL1DTYMK | |
| SCHEMBL22978451 | 0.74 | L3MBTL1 (0.41) | L3MBTL1DTYMK | |
| SCHEMBL22988846 | 0.70 | CSF1R (0.45) | CSF1RKITPDGFRA | |
| SCHEMBL4505573 | 0.68 | L3MBTL1 (0.39) | L3MBTL1DDB1CRBNDTYMK | |
| SCHEMBL21408140 | 0.68 | CSF1R (0.50) | CSF1RKITPDGFRA | |
| SCHEMBL30940044 | 0.67 | L3MBTL1 (0.47) | L3MBTL1DTYMK | |
| SCHEMBL4569771 | 0.67 | L3MBTL1 (0.50) | L3MBTL1DTYMK | |
| SCHEMBL3705482 | 0.67 | L3MBTL1 (0.47) | L3MBTL1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018233526-A9 | CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |